{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=69",
    "query": {
      "condition": "Multi Center",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 6600,
    "total_pages": 660,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T10:50:57.711Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01494584",
      "title": "Study in Pediatric Subjects With Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "ezogabine/retigabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 5,
      "start_date": "2012-07-25",
      "completion_date": "2013-04-29",
      "has_results": true,
      "last_update_posted_date": "2020-11-30",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494584"
    },
    {
      "nct_id": "NCT03519347",
      "title": "Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Potassium Removal Maximization",
          "type": "OTHER"
        },
        {
          "name": "Potassium Gradient Minimization",
          "type": "OTHER"
        },
        {
          "name": "Alkalosis Avoidance",
          "type": "OTHER"
        },
        {
          "name": "Acidosis avoidance",
          "type": "OTHER"
        },
        {
          "name": "Point of Care Testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Cardiac Monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIAGNOSTIC_TEST",
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 19,
      "start_date": "2018-11-30",
      "completion_date": "2022-10-14",
      "has_results": true,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03519347"
    },
    {
      "nct_id": "NCT05799157",
      "title": "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Verruca Vulgaris",
        "Warts",
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "VDMN-21 Patch Low Dose",
          "type": "DRUG"
        },
        {
          "name": "VDMN-21 Patch High Dose",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veradermics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "9 Years to 65 Years"
      },
      "enrollment_count": 153,
      "start_date": "2023-02-28",
      "completion_date": "2025-02-25",
      "has_results": false,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 16,
      "location_summary": "Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05799157"
    },
    {
      "nct_id": "NCT03946072",
      "title": "Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurocognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Transseptal Aortic Approach Catheter Ablation Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Retrograde Aortic Approach Catheter Ablation Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2019-07-02",
      "completion_date": "2023-11-25",
      "has_results": false,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03946072"
    },
    {
      "nct_id": "NCT01214837",
      "title": "Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Disease",
        "Meningococcal Meningitis"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine Vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "55 Days to 89 Days"
      },
      "enrollment_count": 751,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01214837"
    },
    {
      "nct_id": "NCT02952508",
      "title": "Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia",
        "Multiple Myeloma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Marginal Zone Lymphoma",
        "Mantle Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iopofosine I 131 single dose",
          "type": "DRUG"
        },
        {
          "name": "Iopofosine I 131 multiple dose",
          "type": "DRUG"
        },
        {
          "name": "Iopofosine I 131 fractionated dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cellectar Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2017-07-26",
      "completion_date": "2027-12-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952508"
    },
    {
      "nct_id": "NCT03567889",
      "title": "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma Stage IIIB",
        "Melanoma Stage IIIC",
        "Melanoma Stage IIID"
      ],
      "interventions": [
        {
          "name": "Daromun",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Adjuvant therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Philogen S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2018-09-20",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03567889"
    },
    {
      "nct_id": "NCT00240617",
      "title": "Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "sumatriptan succinate/naproxen sodium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 623,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-26",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 52,
      "location_summary": "Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240617"
    },
    {
      "nct_id": "NCT04844840",
      "title": "A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keloid"
      ],
      "interventions": [
        {
          "name": "STP705",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sirnaomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-29",
      "completion_date": "2023-05-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04844840"
    },
    {
      "nct_id": "NCT01970878",
      "title": "Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT 003)",
          "type": "DRUG"
        },
        {
          "name": "GP MDI (PT001)",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005)",
          "type": "DRUG"
        },
        {
          "name": "Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 892,
      "start_date": "2013-11",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-11-09T10:50:57.711Z",
      "location_count": 110,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01970878"
    }
  ]
}